Brief: Novan Announces Preclinical Data And Intent To Advance SB019 For Treatment Of COVID-19

NVN Liquidation

09/11/2021 13:36

Nov 9 (Reuters) - Novan Inc  NOVN.O :
    * NOVAN ANNOUNCES FAVORABLE PRECLINICAL SAFETY DATA AND
INTENT TO
ADVANCE SB019 FOR TREATMENT OF COVID-19
    * NOVAN INC - PRE-IND (INVESTIGATIONAL NEW DRUG) APPLICATION
ACTIVITIES ARE UNDERWAY WITH A TARGET OF AN IND SUBMISSION NO
LATER THAN Q2 2022
    * NOVAN INC - DATA INDICATES INTRANASAL ADMINISTRATION OF
SB019
FORMULATION CONTAINING BERDAZIMER SODIUM IS WELL-TOLERATED AND
SAFE IN PRECLINICAL STUDY

Source text for Eikon:  ID:nGNX66X1JN 
Further company coverage:  NOVN.O 

 ((Reuters.Briefs@thomsonreuters.com;))